Navigation Links
NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position
Date:4/8/2013

DCVax-L for brain cancer, in both the US and Europe;
  • initiation of the DCVax-Direct program;
  • commencement of a "Specials" program (similar to compassionate use) for brain cancer patients not eligible for the Phase III trial in the UK to obtain DCVax-L on a self-pay basis;
  • completion of a 6-month Scientific Advice process with regulators, with positive feedback, and application for a "Hospital Exemption" program (similar to compassionate use) in Germany for brain cancer patients not eligible for the Phase III trial to obtain DCVax-L on a self-pay basis;
  • assistance to 10 major hospital centers in Germany (including all key opinion leaders in brain cancer) preparing and submitting applications to the German healthcare system requesting authorization of reimbursement for DCVax-L;
  • doubling of manufacturing capacity for DCVax-L in US;
  • completion of extensive regulatory processes and inspections, and receipt of approval, for manufacturing of DCVax-L in Germany for Phase III clinical trial; 
  • additional regulatory processes in both UK and Germany for supply of DCVax-L products from Germany to UK for Phase III trial in UK;
  • technology transfer and regulatory processes for manufacturing of DCVax-L in UK;
  • partnering arrangements with several large marquee partners in the US and Europe;
  • initiation of manufacturing preparations in US for DCVax-Direct Phase I/II trial;
  • award of a $5.5 million non-dilutive matching grant from the German government (one of the largest such grants ever awarded), which the Company plans to start drawing  in Q2 of 2013;
  • comprehensive clean-up of the Company's balance sheet (eliminating more than $36 million in debt);
  • financings totaling over $32 million;
  • listing of the Company's Common Stock and Warrants on the Nasdaq Capital Markets;
  • expansion of the Company's management team with a veteran sen
    '/>"/>

  • SOURCE Northwest Biotherapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies
    2. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
    3. Susan Cain Will Kick Off 2013 ASAE Annual Meeting & Exposition, Dan Heath is Closing General Session Speaker
    4. Electronic Headband That Detects and Treats Addictive In-Sleep Behavior to be Demonstrated at Annual Holistic Dental Conference by Holistic Technologies
    5. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
    6. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
    7. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
    8. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
    9. Archimedes Inc. Renews Annual Marketing Agreement with HealthEconomics.Com
    10. Palatin Technologies To Present At The 25th Annual ROTH Conference
    11. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... the right people at the table for significant business ... achieving clinical and operational goals. The 22 nd ... 2014, in San Diego , featured ... discussing how partnerships have positively impacted their objectives. ... Officer of Cape Regional Medical Center located in ...
    (Date:7/23/2014)... , July 23, 2014 ... portfolio company of Trendlines Agtech , announced ... Israel,s leading agricultural thermoplastics ... Valentis,s technology combines nanocrystalline cellulose (NCC), ... waste, with additional nanoparticles to produce highly improved ...
    (Date:7/23/2014)... -- regulated information -- UCB today announced an important ... positive topline results from the latest Phase 3 ... to evaluate the efficacy and safety of ... compared to placebo, as adjunctive treatment in adult ... controlled despite treatment with one or two concomitant ...
    (Date:7/23/2014)... July 23, 2014  Sofinnova Ventures, a ... the closing of Sofinnova Venture Partners IX, L.P. at ... of the initial fund target of $425 million. ... biotechnology companies. Consistent with recent funds, SVP IX will ... clinical programs, along with select investments in earlier stage ...
    Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2
    ... - YM BioSciences Inc. (NYSE Alternext US:YMI, ... develops and commercializes differentiated products for patients ... clearance from Canadian regulatory authorities to initiate ... nimotuzumab, its EGFR-targeting antibody, in combination with ...
    ... Start of Q4 2008 , - Evaluation of strategic alternatives ... RoleSAN DIEGO, Jan. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext ... reduction-in-force in an effort to extend its remaining cash and ... a reduction implemented in October 2008. In all, the ...
    ... Jan. 5 LightLab Imaging Inc. today,announced ... past year that are,the culmination of sustained ... These advances significantly increase the Company,s leadership,position ... OCT is a new,high-resolution, high-speed imaging ...
    Cached Biology Technology:YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7ADVENTRX Announces Further Cost-Cutting Measures 2ADVENTRX Announces Further Cost-Cutting Measures 3ADVENTRX Announces Further Cost-Cutting Measures 4ADVENTRX Announces Further Cost-Cutting Measures 5LightLab Imaging Leads Global Advancement of Intracoronary Imaging 2LightLab Imaging Leads Global Advancement of Intracoronary Imaging 3
    (Date:7/23/2014)... drought that has the entire country in its grip is ... also be responsible for the proliferation of a heat-loving amoeba ... and hot springs, which the drought has made warmer than ... of an infection caused by this parasite after swimming in ... nose of an individual and travels to the brain. Nose ...
    (Date:7/23/2014)... The Worldwide Innovative Networking in personalized cancer medicine, ... Cancer Center at Thomas Jefferson University will ... only member of this prestigious group in the Tri-State ... delivery of innovative personalized medicine to the patient by ... advocacy. , "Our participation in the WIN consortium means ...
    (Date:7/23/2014)... play an increasingly important role in carbon and nutrient ... expand, according to research published this week in the ... , University of British Columbia researchers plumbed the depth ... chart how microbial community metabolism changes as oxygen minimum ... picture of how SUP05 a bacterial group related ...
    Breaking Biology News(10 mins):Diseases of another kind 2New partnership brings more personalized cancer treatment to Philadelphia 2Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
    ... New Rochelle, NY, September 9, 2010A subset of ... associated with more illness and greater allergic hypersensitivity, ... Blood, and Lung Institute,s Severe Asthma Research Program ... Pediatric Allergy, Immunology, and Pulmonology , a ...
    ... The National Institutes of Health is launching two major ... curtail the nation,s childhood obesity epidemic. One will ... and the other will examine community efforts to reduce ... public health concern. If we don,t curb this widespread ...
    ... USDA Agriculture and Food Research Initiative (AFRI) grant will help ... gene system of sorghum will lead to enhanced bioenergy production ... we already know about and tailoring them to bioenergy uses ... professor of crop sciences and member of the Energy Biosciences ...
    Cached Biology News:Research and insights on severe asthma in children 2NIH-funded studies aim to prevent, treat childhood obesity 2NIH-funded studies aim to prevent, treat childhood obesity 3U of I receives $1 million USDA grant to study Glossy15 in sorghum 2
    Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
    RECK (F-20)...
    The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
    NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
    Biology Products: